Shares of Motus GI Hldgs MOTS were flat after the company reported Q2 results. Quarterly Results Earnings per share increased 42.31% year over year to ($0.15), which beat the estimate of ($0.21). Revenue of
Shares of Motus GI Hldgs MOTS decreased 4.8% after the company reported Q2 results.
Quarterly Results
Earnings per share increased 42.31% year over year to ($0.15), which beat the estimate of ($0.21).
Revenue of $1,000 decreased by 75.00% from the same period last year, which missed the estimate of $20,000.
Outlook
Motus GI Hldgs hasn't issued any earnings guidance for the time being.
Motus GI Hldgs hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Aug 11, 2020
Time: 04:30 PM
ET Webcast URL: http://public.viavid.com/player/index.php?id=140402
Recent Stock Performance
52-week high: $2.99
52-week low: $0.46
Price action over last quarter: Up 12.26%
Company Description
Motus GI Holdings Inc is a medical technology company dedicated to improving endoscopy outcomes, lowering costs and enhancing patient experiences. The company is focused on the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
